Alveolar Macrophage Proteomics in HIV-associated Emphysema
This trial is active, not recruiting.
|Conditions||hiv, emphysema, hiv infections|
|Collaborator||National Institutes of Health (NIH)|
|Start date||March 2006|
|End date||December 2015|
|Trial size||365 participants|
|Trial identifier||NCT00823927, 2005H0197|
This study is being done to examine lung function changes in individuals with HIV infection and to understand why individuals with HIV have increased risk of lung damage from cigarette smoking.
|Observational model||case control|
HIV smokers with emphysema
HIV smokers without emphysema
examine the natural history of smoking related lung damage in patients with HIV
time frame: 3 years
Male or female participants at least 18 years old.
Inclusion Criteria: - Clinically stable HIV-seropositive (and HIV-seronegative) individuals - Ages 18 years and older - Female subjects on no oral contraception with a negative pregnancy test - Subjects capable of giving written consent Exclusion Criteria: - Known medical illness that would preclude bronchoscopy/BAL (e.g. unstable angina, new cardiac arrhythmia). This only pertains to subjects involved in the bronchoscopy phase of the study. - Pregnant females - Prisoners
|Official title||Alveolar Macrophage Proteomics in HIV-associated Emphysema|
|Principal investigator||Philip T Diaz, MD|
|Description||To delineate the natural history of HIV associated emphysema in the HAART era. To compare the alveolar macrophage proteomes from HIV-seropositive smokers with emphysema to the alveolar macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers. To establish whether coinfection with HIV and Hepatitis C results in accelerated lung disease manifested by decrements in forced expiratory volume and carbon monoxide diffusing capacity.|
Call for more information